Brief: Cohbar Announces First Subjects Dosed In Its Phase 1B Clinical Trial For Cb4211 Under Development For Nash And Obesity
24/08/2020 14:25
Aug 24 (Reuters) - CohBar Inc CWBR.O :
* COHBAR ANNOUNCES FIRST SUBJECTS DOSED IN ITS PHASE 1B
CLINICAL
TRIAL FOR CB4211 UNDER DEVELOPMENT FOR NASH AND OBESITY
* COHBAR INC - TOPLINE DATA CURRENTLY PROJECTED IN Q1 2021
Source text for Eikon: ID:nGNX3D8wql
Further company coverage: CWBR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CohBar
See all newsBrief: CohBar, Inc. Q2 EPS USD -1.49
Brief: Morphogenesis And CohBar Announce Positive Results From Phase 1B Trial Of IFX-HU2.0 Personalized Cancer Vaccine, In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) And Cutaneous Squamous Cell Carcinoma (CSCC)
U.S. STOCKS ON THE MOVE-Galecto, Pinterest, Standard Lithium
CohBar surges on merger agreement with Morphogenesis
U.S. STOCKS ON THE MOVE-Chevron, Broadcom, Williams-Sonoma